<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881517</url>
  </required_header>
  <id_info>
    <org_study_id>FARM7J4HCH</org_study_id>
    <nct_id>NCT00881517</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection</brief_title>
  <acronym>CHIP</acronym>
  <official_title>Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to verify, under controlled conditions, the reported efficacy of
      human cytomegalovirus (HCMV)-specific hyperimmune globulin administration to pregnant women
      suffering from primary HCMV infection for the prevention of intrauterine HCMV transmission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCMV is the leading infectious cause of mental retardation and deafness in infants with
      congenital HCMV infection. Primary HCMV infections during pregnancy carry the highest risk of
      fetal infection and disease. No intervention of proven efficacy is available in case of
      primary HCMV infection in pregnancy. However, a study published in 2005 (Nigro et al., NEJM
      353:1350-62, 2005) reported that in pregnant women with primary HCMV infection treated with
      HCMV-specific hyperimmune globulin (Cytotect®, Biotest) the risk of transmitting the
      infection to the fetus was reduced from 40% to 16%. Unfortunately, since the study was
      conducted with inadequate controls, the actual efficacy of hyperimmune globulin could not be
      properly assessed.

      In the present randomized, double-blind, placebo-controlled, multicenter trial pregnant women
      with ascertained primary HCMV infection at 4-26 weeks of gestation will be randomized to
      receive Cytotect® or placebo intravenously within 6 weeks after the presumed onset of
      infection.

      Primary efficacy parameter will be the number of HCMV-infected newborns or fetuses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of congenital HCMV infection in the fetus/newborn</measure>
    <time_frame>At amniocentesis and/or within one week after birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCMV-specific immune response (humoral and cell-mediated)</measure>
    <time_frame>36-48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological and histological findings in placentas</measure>
    <time_frame>36-48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome of newborns with congenital HCMV infection</measure>
    <time_frame>within 2 weeks after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Cytotect in the mother and newborn</measure>
    <time_frame>within 24 hours after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>Cytotect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCMV-specific hyperimmune globulin (Cytotect®)</intervention_name>
    <description>100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.</description>
    <arm_group_label>Cytotect</arm_group_label>
    <other_name>Cytotect®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic solution of sodium chloride (placebo)</intervention_name>
    <description>2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women (in vitro fertilization permitted)

          -  &gt;= 18 years of age

          -  primary HCMV infection at 5-26 weeks' gestation

          -  &lt;= 6 weeks from presumed onset of infection

          -  gestational age between 5-32 weeks' gestation

          -  written informed consent

        Exclusion Criteria:

          -  multiple pregnancy

          -  history of HIV or HBV or HCV infection

          -  known immunodeficiency or immunosuppression

          -  congenital or acquired autoimmune disease

          -  known intolerance to protein of human origin

          -  known intolerance to immune globulin

          -  history of adverse effects to vaccination

          -  hypersensitivity to human immune globulin (pathological IgG or IgA deficiences)

          -  renal failure

          -  serious organic or psychiatric disease

          -  lack of motivation to participate in the study

          -  women unable to satisfy study requirements

          -  women not willing or unable to provide written informed consent

          -  women not willing to give consent to transmission of anonymised data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Grazia Revello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC Ostetricia e Ginecologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Ostetricia e Ginecologia, Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina dell'Età Prenatale, Ospedale Policlinico S.Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Materno-Fetale, Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Malattie Infettive, IRCCS Istituto G.Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento per la salute della donna, del bambino e del neonato. Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostetricia e Ginecologia, Ospedale V.Buzzi</name>
      <address>
        <city>Milano</city>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Semplice di Ostetricia, Ospedale Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ostetrica e Ginecologica, Ospedale S. Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostetricia e Ginecologia, Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ostetricia e Ginecologia a indirizzo materno fetale, Dipartimento di Discipline Ginecologiche e Ostetriche, Università di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ostetricia e Ginecologia, IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Maria Grazia Revello</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <keyword>human cytomegalovirus</keyword>
  <keyword>immune globulin</keyword>
  <keyword>congenital infection</keyword>
  <keyword>prevention</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

